Coating and modification of a prostate-selective oncolytic adenovirus to enable systemic delivery, eliminate metastases and induce tumour immunity.
Applications are sought for a Postdoctoral Research Assistant to develop a novel therapeutic strategy for late stage prostate cancer using our recently engineered oncolytic adenoviruses.
In this project we will develop a novel therapeutic strategy for late stage prostate cancer using our recently engineered oncolytic adenoviruses. The oncolytic mutants selectively kill cancer cells with robust efficacy and therapeutic activity in preclinical models of prostate cancer, including monolayer and 3-dimensional co-cultures, and in vivo (Man et al, MCT 2018; Aguirre-Hernandez, Oncogenesis 2018). In addition, the genetically altered oncolytic viruses promote drug-mediated cytotoxicity through multiple mechanisms, re-sensitizing drug-resistant tumours. To reach distant tumour lesions after systemic administration, the oncolytic mutants need to be protected from blood factor-binding and the rapid hepatic elimination. The postdoctoral researcher will identify and optimize the encapsulated virus complexes for increased circulatory half-life, tumour cell lysis and spread within the tumour microenvironment in preclinical cell culture and in vivo models. A major part of the project is to further modify the virus package to activate host anti-tumour immune responses by arming with immune stimulatory factors to promote long-term immunity to prostate cancer. The overall aim of this project is to develop an oncolytic adenovirus-based delivery system to target and eliminate metastatic lesions after systemic delivery to treat late-stage prostate cancer patients and promote host anti-tumour immune responses. By increasing the viral dose at the sites of cancer lesions, increased tumour lysis and presentation of tumour antigens will be realised. To take advantage of the improved lysis, the coated virus will be armed with immune stimulatory factors to further promote anti-tumour long-term immunity to prostate cancer.
Application closing date: 18th October 2018
Job listing informationMore Information